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ABSTRACT
The nomenclature committee of the International Society of Amyloidosis (ISA) meets every second
year to discuss and formulate recommendations. The conclusions from the discussion at the XVI
International Symposium on Amyloidosis in Kumamoto, Japan, 25–29 March 2018 and afterwards are
summarized in this Nomenclature Article. From having recommended the use of the designation
“amyloid fibril” for in vivo material only, ISA’s nomenclature committee now accepts its use more
broadly following the international scientific literature. However, it is important always to stress the
origin of the b-fibrils in order to avoid misunderstanding. Given the more broad use of the word
“amyloid” several classes of amyloid fibrils may be distinguished. For the medical in vivo situation, and
to be included in the amyloid nomenclature list, “amyloid” still means mainly extracellular tissue
deposits of protein fibrils, recognized by specific properties, such as green-yellow birefringence after
staining with Congo red. It should also be underlined that in vivo amyloid fibrils, in addition to the
main protein contain associated compounds, particularly serum amyloid P-component (SAP) and pro-
teoglycans, mainly heparan sulfate proteoglycan. With this definition there are presently 36 human
amyloid proteins of which 14 appear only associated with systemic amyloidosis and 19 as localized
forms. Three proteins can occur both as localized and systemic amyloidosis. Strictly intracellular aggre-
gates are not included in this list.
Abbreviations: AL: amyloid light chain; ATTR: amyloid transthyretin; ISA: International Society of
Amyloidosis; LRG: locus reference genomic
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Introduction
Since the second International Symposium on Amyloidosis
in Helsinki, Finland in 1974 a nomenclature committee
has met, officially recognized diseases related to the depos-
ition of new amyloid proteins, discussed nomenclature
problems and given recommendations. Since our journal
started, these recommendations have been published
in Amyloid.
The Nomenclature Committee of ISA met at the XVI
International Symposium on Amyloidosis in Kumamoto,
Japan, 25–29 March 2018 and current problems were dis-
cussed. Two new members were welcomed: David
Eisenberg, USA and Yoshiki Sekijima, Japan. The basic
nomenclature, most recently defined in 2016 [1],
was confirmed.
Amyloid
The word “amyloid” is an enigmatic one that needs to be
precisely defined. It means literally starch-like (amylon
(Greek), amylum (Latin) is starch) and was originally used
in botany but adopted by Rudolf Virchow 1854 to be used
for the material we today call AA amyloidosis.
Subsequently, when more defining histologic staining meth-
ods were developed, particularly Congo red combined with
polarization microscopy, it was discovered that a number of
similar mainly extracellular deposits could be identified in
different tissues and each was usually associated with a spe-
cific disease. In order to differentiate these heterogeneous
groups of deposits from the typical ones identified by
Virchow, different names were given, e.g. para-amyloid.
Para-amyloid was also a problematic name; it was
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sometimes used for amyloid associated with myeloma (AL
amyloid) or pancreatic islet amyloid in diabetes (AIAPP
amyloid according to our present nomenclature). The
nomenclature was purely descriptive since the biochemical
nature was unknown. In 1959 Cohen and Calkins showed
that the light microscopically hyaline-appearing amyloid in
reality is composed of fibrils around 10 nm in width of
indeterminate length. The next critical analytic step was the
finding by Glenner and coworkers that the protein fibrils
are aligned as “cross b-sheets” [2]. All this basic knowledge
came from the medical field. Subsequently and most
importantly it was demonstrated that a number of different
polypeptides aggregate into in vivo amyloid deposits and
that fibrils in any given patient’s tissues were generally
formed from a single protein precursor.
In human and veterinary medical practice amyloid is a
pathological deposited proteinaceous material, recognized by
certain properties and appearance. However, as is described
below, the word amyloid is now used much more broadly.
Amyloidosis
Amyloidosis is a disease associated with deposits of amyloid
fibrils found in humans and in many other vertebrate spe-
cies. The designation amyloidosis is nowadays mainly used
for systemic disease in which the aggregated proteins defin-
itely are pathogenic. The situation is more complicated with
localized forms. For example, although tumor-like AL amyl-
oid (“amyloidoma”) should be accepted as amyloidosis, the
question of disease causation of amyloid is still uncertain in
conditions such as Alzheimer’s disease and type 2 diabetes.
Although protein aggregation and amyloid formation are
typical in both these diseases and most likely involved in
their pathogenesis, they are still not primarily defined as
amyloidoses but this may change in the future.
Amyloid fibril
The fibril constitutes the main component of amyloid
deposits. It also determines many main properties of the
material and of the amyloid diseases, including persistence
and seeding behavior. The amyloid fibril is a polymeric
structure in which protein backbones arranged in b second-
ary structure are hydrogen-bonded, forming long protofila-
ments. Two or more identical protofilaments interact via
their sidechains to form the characteristic fibrils which are
around 10 nm in diameter. This principal structure of the
fibril can be mimicked in vitro with the use of well-defined
peptides, also from peptides not appearing as in vivo amyl-
oid. The hydrogen bonding of the peptide backbone as well
as participation of sidechains have been analyzed in
detail [3,4].
Although it is clear that there is no amyloid without
fibrils, there are also other components present in the
deposits. Some of them are more or less ubiquitous, particu-
larly serum amyloid P-component (SAP) and heparan sul-
fate proteoglycan (HSPG). These are closely associated with
the fibrils. There are in addition several other components
present in the deposits such as several apolipoproteins.
While the association of proteoglycans and SAP with amyl-
oid has been studied in detail much less is known about the
other components. The importance of the associated com-
ponents for development of in vivo amyloid and for its per-
sistence is still unclear.
Understanding the nature of the fibrils inspired George
Glenner, the discoverer of the b-structure of amyloid fibrils,
to suggest a new name for the diseases: b-fibrilloses [5].
However, and perhaps unfortunately, this nomenclature
never took root. Even if the fibrils are the main component
of in vivo amyloid they do not necessarily explain all of its
properties. SAP may be of central importance for the resist-
ance to degradation of amyloid fibrils [6] and bound HSPG,
which explains the acidic character of amyloid and some
specific staining properties, may interact with and influence
cells at deposits.
The problem of nomenclature is that at present the med-
ical and biophysical scientific communities are using differ-
ent definitions of "amyloid". The designation amyloid came
from the medical field but has been adopted by biochemists
and biophysicists and is now generally used for all cross
b-sheet fibrils. This use is fully established in the biochem-
ical-biophysical field. The ISA Nomenclature Committee
had earlier recommended the use of “amyloid-like” for such
fibrils but given the situation we accept “amyloid fibrils”
also for other b-sheet fibrils. However, for clarity the origin
must always be described. The word “amyloid”, without fur-
ther explanation should be restricted to in vivo or ex
vivo deposits.
Functional amyloid
Another nomenclature-related consideration has emerged
with the use of the concept “functional” or non-pathologic
amyloid. Structurally robust, protease resistant b-sheet fibril-
lar assemblies occur widely in nature, particularly in inverte-
brates, e.g. insects, spiders and also bacterial biofilms. In
addition, it has been suggested that some human structures,
such as the p-mel framework in melanosomes and some
polypeptide hormones when stored in secretory vesicles,
have an amyloid fibril structure (reviewed in [7]). These
more broadly applied circumstances have made it increas-
ingly important to use clear definitions when using the
words “amyloid” and “amyloidosis”.
Amyloid fibril classes
As described above, “amyloid” is used for several different
natural and synthetic materials. The situation is becoming
even more complicated now that cell biologists are begin-
ning to use the term “amyloid-like” for a different type of
fiber, those that form from the low-complexity domains of
hydrogels [8]. There may be a need of creating terms for at
least five classes of related fibrils:
1. In vivo and ex vivo disease-related fibrils
2. In vivo and ex vivo functional fibrils
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3. Recombinant fibrils of disease-related proteins and of
functional “amyloid” proteins
4. Fibrils from synthetic or non-disease-related peptides
5. Fibrils from hydrogels that give the cross-b diffrac-
tion pattern.
Currently, we recommend that use of “amyloid” (without
further explanation such as “amyloid state” or “functional
amyloid”) and “amyloidosis” be restricted to pathological
deposits in human and animal medical field. “Amyloid
fibrils”, “amyloid state” etc. can be used more broadly but
have to be defined. However, this is a provisional recom-
mendation and the subject will be discussed further.
Amyloid fibril protein nomenclature in
medical practice
Given the relatively diverse use of “amyloid fibril” a clear
definition of “amyloid” and “amyloidosis” is necessary in
medical practice. In human and veterinary medicine
“amyloid” means mainly extracellular deposits of a fibrillary
protein with particular properties, which make them recog-
nizable by different methods including affinity of Congo red
and yellow-green birefringence after such staining. A num-
ber of proteins (presently 36 in human and 10 in other ver-
tebrates) have been identified (Tables 1 and 2) and more
are to be expected.
Table 1. Amyloid fibril proteins and their precursors in humana.
Fibril protein Precursor protein Systemic and/or localized Acquired or hereditary Target organs
AL Immunoglobulin light chain S, L A, H All organs, usually except CNS
AH Immunoglobulin heavy chain S, L A All organs except CNS
AA (Apo) Serum amyloid A S A All organs except CNS
ATTR Transthyretin, wild type S A Heart mainly in males, Lung,
Ligaments, Tenosynovium
Transthyretin, variants S H PNS, ANS, heart, eye, leptomen.
Ab2M b2-Microglobulin, wild type S A Musculoskeletal System
b2-Microglobulin, variant S H ANS
AApoAI Apolipoprotein A I, variants S H Heart, liver, kidney, PNS, testis,
larynx (C terminal variants),
skin (C terminal variants)
AApoAII Apolipoprotein A II, variants S H Kidney
AApoAIV Apolipoprotein A IV, wild type S A Kidney medulla and systemic
AApoCII Apolipoprotein C II, variants S H Kidney
AApoCIII Apolipoprotein C III, variants S H Kidney
Agel Gelsolin, variants S H PNS, cornea
ALys Lysozyme, variants S H Kidney
ALECT2 Leukocyte Chemotactic Factor-2 S A Kidney, primarily
AFib Fibrinogen a, variants S H Kidney, primarily
ACys Cystatin C, variants S H PNS, skin
ABri ABriPP, variants S H CNS
ADan ADanPP, variants L H CNS
Ab Ab protein precursor, wild type L A CNS
Ab protein precursor, variant L H CNS
AaSyn a-Synuclein L A CNS
ATau Tau L A CNS
APrP Prion protein, wild type L A CJD, fatal insomnia
Prion protein variants L H CJD, GSS syndrome,
fatal insomnia
Prion protein variant S H PNS
ACal (Pro)calcitonin L A C-cell thyroid tumors
AIAPP Islet amyloid polypeptide L A Islets of Langerhans,
insulinomas
AANF Atrial natriuretic factor L A Cardiac atria
APro Prolactin L A Pituitary prolactinomas,
aging pituitary
AIns Insulin L A Iatrogenic, local injection
ASPC Lung surfactant protein L A Lung
AGal7 Galectin 7 L A Skin
ACor Corneodesmosin L A Cornified epithelia, hair follicles
AMed Lactadherin L A Senile aortic media
AKer Kerato-epithelin L A Cornea, hereditary
ALac Lactoferrin L A Cornea
AOAAP Odontogenic ameloblast-
associated protein
L A Odontogenic tumors
ASem1 Semenogelin 1 L A Vesicula seminalis
AEnf Enfurvitide L A Iatrogenic
ACatK Cathepsin K L A Tumor associated
aProteins are listed, when possible, according to relationship. Thus, apolipoproteins are grouped together, as are polypeptide hormones.ADan is the product of the same gene as ABri.Also called amylin.Not proven by amino acid sequence analysis.Full amino acid sequence to be established.
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Name of amyloid proteins and associated diseases
The amyloid fibril protein is designated protein A and fol-
lowed by a suffix that is an abbreviated form of the parent
or precursor protein name. This designation should also be
used for the associated amyloid disease. For example, when
amyloid fibrils are derived from immunoglobulin light
chains, the amyloid fibril protein is AL and the disease is
AL amyloidosis. Amyloid transthyretin is ATTR and the dis-
ease is ATTR amyloidosis. Importantly, AL or ATTR are
not diseases; AL and ATTR are the disease causing proteins.
Amyloid protein variants
As stated in the previous Nomenclature Guidelines [1]
“amyloid fibril protein variants are named according to the
substitution or deletion in the mature amyloid protein, e.g.
ATTRV30M or ALysI56T and this principle should continue
to be followed. The Sequence Variant Description Working
Group (SVDWG) convened by the Human Genome
Variation Society recommends that observations be reported
using an appropriate reference sequence, i.e. when genomic
DNA is sequenced, a genomic DNA sequence is the pre-
ferred reference and (by inference) when a protein sequence
is reported, an amino acid sequence is the preferred refer-
ence. The working group further recommends the use of
the recently introduced Locus Reference Genomic sequence
(LRG) (http://www.lrg-sequence.org/; the LRG collaboration
maintains and creates LRGs [6]. While the SVD-WG prefers
the three letter amino acid designation to avoid confusion,
the group finds the single letter amino acid code acceptable;
we recommend use of the single letter amino acid code and
the sequence numbering of the mature protein when report-
ing studies on amyloid proteins.”
Amyloid disease nomenclature
The diseases known as the amyloidoses result from the sys-
temic or localized deposition of amyloid fibrils in the extra-
cellular spaces of organs and tissues. Since the previous
Nomenclature Meeting in Uppsala 2016 one new protein
has been identified as amyloid fibril components in human,
cathepsin K, found localized to an angiomyolipoma [9].
Since the full amino acid sequence was not available it was
not established whether the protein was wild-type or vari-
ant. For further description of the amyloid conditions please
see previous publication [1]. For current proteins, see Table
1. New protein variants, particularly TTR are continuously
reported and these can be found in [10].
The name “hereditary” is recommended rather than
“familial”. Thus, diseases depending on a mutation in the TTR
gene should be called “hereditary ATTR (ATTRv; v for vari-
ant) amyloidoses”. By fulfilling a patients” wish we now rec-
ommend ATTRv instead of ATTRm. The designations
“familial amyloid polyneuropathy” and “familial amyloid car-
diomyopathy” should be regarded as outdated and as exact as
possible name should be used. An example is “ATTRV30M
amyloidosis”. Descriptions of major clinical presentation can
be added, for example “with cardiomyopathy”.
Amyloid proteins in animals
The number of known amyloid proteins in animals is 10, of
which only one is not seen in human (Table 2). No heredi-
tary forms are known.
Table 2. Amyloid fibril proteins and their precursors in animals.
Fibril protein Precursor protein Systemic and/or localized Affected organs or syndrome Species
AL Immunoglobulin Light Chain S,L Plasmacytoma Cat, Horse
AA (Apo) Serum Amyloid A S Chronic Inflammation
or Infections
Many mammalian and avian
species: Mouse, Cat, Cow,
Dog, Duck, Guinea pig, etc.
AApoAI Apolipoprotein AI S Age-related Dog
AApoAII Apolipoprotein AII S Age-related Mouse
ATTR Transthyretin S Age-related Vervet monkey
AFib Fibrinogen Aa S Spleen, Liver Stone marten
Ab Ab precursor protein L Age-related Dog, Sheep, Wolverine
AIAPP Islet Amyloid Polypeptide L Islets of Langerhans, Insulinoma Apes, Cat, Racoon
AIns Insulin L Islets of Langerhans Octodon degus
ACas A-S2C casein L Mammary gland Cow
Table 3. Intracellular inclusions with known biochemical composition, with or without amyloid properties.
Inclusion name Site Protein nature Examples of associated disease
Lewy bodies Neurons ntracytoplasmic a-synuclein,  Parkinson’s disease
Huntington bodies Neurons intranuclear PolyQ expanded huntingtin Huntington’s disease
Hirano bodies Neurons Actin Neurodegenerative disorders
Collins bodies Neurons Neuroserpin Forms of familial presenile dementia
Not specified Neurons, many different cells Ferritin Form of familial neurodegenerative disorder
Neurofibrillary tangles Neurons Intracytoplasmic Tau Alzheimer disease, fronto-temporal dementia, aging,
other cerebral conditions
AaSyn Neurons Intracytoplasmic a-synuclein Parkinson disease, other cerebral conditions
Simplified. Additional components may exist.Also included in Table 1 since deposits may appear extracellularly.
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Intracellular inclusions
Intracellular inclusions with or without amyloid staining
properties are given in Table 3.
Specific recommendations
1. Amyloid fibrils are not uniform and several “classes”
can be recognized. When the word “amyloid” is used a
more precise definition is therefore necessary.
2. AL, ATTR, etc. are amyloid protein names. Corresponding
diseases are AL amyloidosis, ATTR amyloidosis and so on.
3. Diseases depending on amyloid protein gene mutations
are “hereditary” and should not be called “familial”.
The designations “familial amyloid polyneuropathy,
FAP”, or “familial amyloid cardiomyopathy, FAC”
should be not used.
4. A variant amyloid fibril protein is best defined by exact
description of the mutation. The variant should be
defined by one-letter-code and be numbered from the
mature protein, e.g. ATTRV122I or ATTRV30M.
Instead of the exact mutation the designation ATTRv
(variant) can be used and is preferred to
ATTRm (mutant).
5. Please see also recommendations in the previous
Nomenclature Article [1].
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